Skip to main content

Link William J PhD's Form 4 filing

Oyster Point Pharma, Inc.OYST · filed Oct 20, 2021

Accession no.
0001209191-21-061153
Filed
Oct 20, 2021
Trade date
Oct 18, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions. Open-market sales total $8.16M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Link William J PhDCIK 0001228684Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 18, 2021Common StockSSaleDisposed−303,614$14.63F2−$4,441,872.821,057,976IndirectDuplicate filing
Oct 18, 2021Common StockSSaleDisposed−242,943$15.09F4−$3,666,009.87815,033IndirectDuplicate filing
Oct 18, 2021Common StockSSaleDisposed−1,912$14.63F2−$27,972.566,518IndirectDuplicate filing
Oct 18, 2021Common StockSSaleDisposed−1,531$15.09F4−$23,102.794,987IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $14.00 to $14.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote to this Form 4.

Referenced by the price of 2 transactions in Table I.

F4

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $15.00 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote to this Form 4.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)